heterozygous familial hypercholesterolemia

Eli Lilly and Co. has agreed to buy Verve Therapeutics Inc. for up to $1.3 billion, in a move that bolsters Lilly’s push into gene editing for cardiovascular conditions and signals renewed confidence in the sector. The all-cash tender offer values Verve at $10.50 per share upfront. That’s a 113% premium over the company’s 30-day…

Nexletol is similar to Nexlizet in its FDA indication as an adjunct to diet and statin therapy to treat adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease who need additional help lowering of LDL cholesterol. In September, Nexletol began a direct-to-consumer campaign advertising the potential of the drug to support LDL cholesterol-lowering as an adjunct…

Nexlizet from Esperion is FDA-indicated for heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease. The indication is intended as an adjunct to diet and statin therapy for patients who need additional help reducing LDL cholesterol levels. The drug, which combines two cholesterol-reducing medicines (bempedoic acid and ezetimibe), won FDA approval early last year.